Patients in the necitumumab plus pemetrexed and cisplatin group had more grade @-@ rash ( @ -LSB- @ % -RSB- of @ vs one -LSB- < @ % -RSB- of @ patients in the pemetrexed and cisplatin alone group ) , hypomagnesaemia ( @ -LSB- @ % -RSB- vs seven -LSB- @ % -RSB- patients ) , and grade @ or higher venous thromboembolic events ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- patients ) than did those in the pemetrexed and cisplatin alone group .